Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2018

Study Completion Date

June 30, 2018

Conditions
Colorectal CancerLiver Metastasis
Interventions
DRUG

Bevacizumab, mFOLFOX, FOLFIRI

"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"

DRUG

Bevacizumab, mFOLFOX, FOLFIRI

"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"

Trial Locations (1)

Unknown

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01632722 - Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets | Biotech Hunter | Biotech Hunter